Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 8/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641619 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13641685 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13641455 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13641446 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13641450 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13641440 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13641601 | 1.00 | VDR (0.65) | VDRHDAC6HDAC3CYP24A1HDAC2 | |
| SCHEMBL13824927 | 0.93 | VDR (0.66) | VDR | |
| SCHEMBL13824922 | 0.93 | VDR (0.66) | VDR | |
| SCHEMBL13824842 | 0.93 | VDR (0.66) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283228-A1 | 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012151420-A1 | 2α-METHYL AND 2β-METHYL ANALOGS OF 19,26-DINOR-1α, 25-DIHYDROXYVITAMIN D3 AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120283228-A1 | 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283228-A1 | 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses | CYP24A1, VDR, CYP27B1 | VDR 2/4885HDAC6 4745/4885HDAC3 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.